Clinical Trials Browser

Hodgkin Disease × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all

Hodgkin Disease, Leukemia, Lymphoma, Neoplasms, Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT02593123 2023-01-23

Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Leukemia, Lymphoid, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

NCT00952237 2018-04-25

Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF

Phase 1 Completed

13 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Amyloidosis, Hodgkin Disease, Leukemia, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT01158118 2017-06-05

Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors

Phase 2 Completed

48 enrolled 17 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00533923 2016-07-18

Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders

Phase 2 Completed

25 enrolled

Classical hematologyLymphoidMyeloidPlasma cell

Anemia, Aplastic, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis

Clinical Trials

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis

Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF

Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors

Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders